文章摘要
黄仲略,高翔,王辉,邓流飞,黄菲菲,汪晓燕.瑞舒伐他汀钙联合美托洛尔对冠心病合并心力衰竭患者血浆氨基末端脑肽钠前体水平的影响[J].中国临床保健杂志,2020,23(2):226-229.
瑞舒伐他汀钙联合美托洛尔对冠心病合并心力衰竭患者血浆氨基末端脑肽钠前体水平的影响
Effect of rosuvastatin combined metoprolol on plasma NT-proBNP of patients with coronary heart disease complicated with heart failure
投稿时间:2019-07-10  
DOI:10.3969/J.issn.1672-6790.2020.02.022
中文关键词: 冠心病  心力衰竭  美托洛尔  瑞舒伐他汀钙  利钠肽,脑
英文关键词: Coronary disease  Heart failure  Metoprolol  Rosuvastatin calcium  Natriuretic peptide,brain 〖FL
基金项目:
作者单位E-mail
黄仲略 华中科技大学协和江北医院心内科,武汉 430100 vtj52p@163.com 
高翔 华中科技大学协和江北医院心内科,武汉 430100  
王辉 华中科技大学协和江北医院心内科,武汉 430100  
邓流飞 华中科技大学协和江北医院心内科,武汉 430100  
黄菲菲 华中科技大学协和江北医院心内科,武汉 430100  
汪晓燕 华中科技大学协和江北医院心内科,武汉 430100  
摘要点击次数: 292
全文下载次数: 307
中文摘要:
      目的 探讨瑞舒伐他汀钙联合美托洛尔对冠心病合并心力衰竭患者血浆氨基末端脑肽钠前体(NT-proBNP)的影响及其作用机制。方法 按随机数字法将156例住院冠心病合并心力衰竭患者分为两组,每组78例。对照组给予常规治疗,观察组在对照组基础上加用瑞舒伐他汀钙与美托洛尔,两组均治疗12周。治疗后,比较两组血浆NT-proBNP、心功能[收缩末期左心室内径(LVESD)、舒张末期左心室内径(LVEDD)、左室射血分数(LVEF)]、炎性因子[超敏C反应蛋白(hs-CRP)、肿瘤坏死因子α(TNF-α)、白细胞介素-18(IL-18)]、神经内分泌及相关因子[血管紧张素Ⅱ(Ang Ⅱ)、精氨酸加压素(AVP)、醛固酮(ALD)]水平的变化。结果 治疗后,两组血浆NT-proBNP水平显著降低(P<0.05),且观察组明显低于对照组(P<0.05)。治疗后,两组LVESD、LVEDD水平明显降低(P<0.05),且观察组显著低于对照组(P<0.05);两组LVEF水平明显升高(P<0.05),且观察组显著高于对照组(P<0.05)。治疗后,两组hs-CRP、TNF-α、IL-18水平明显降低(P<0.05),且观察组显著低于对照组(P<0.05)。治疗后,两组Ang Ⅱ、AVP、ALD水平显著降低(P<0.05),且观察组明显低于对照组(P<0.05)。结论 瑞舒伐他汀钙联合美托洛尔可明显改善冠心病合并心力衰竭患者心功能,降低血浆NT-proBNP水平,其作用机制可能与联合用药可下调炎性因子及神经内分泌水平,抑制心肌重塑有关。
英文摘要:
      Objective To investigate the effect of rosuvastatin combined metoprolol on plasma NT-proBNP in patients with coronary heart disease complicated with heart failure and its mechanism.Methods Randomized digital method was used to divide 156 patients with coronary heart disease and heart failure into two groups,with 78 patients in each group.The control group received conventional treatment,and the observation group was given rosuvastatin and metoprolol based on treatment of the control group.Both groups were treated for 12 weeks.After treatment,the changes of levels ofplasma NT-proBNP,cardiac function (LVESD,LVEDD,LVEF),inflammatory factors (hs-CRP,TNF-α,IL-18),neuroendocrine and related factors (Ang Ⅱ,AVP,ALD) in two groups were compared.Results After treatment,the levels of plasma NT-proBNP were significantly decreased in two groups (P<0.05),and the levels of plasma NT-proBNP in the observation group was significantly lower than those in the control group(P<0.05);the levels of LVESD and LVEDD were significantly decreased in two groups(P<0.05),and the levels of LVESD and LVEDD in the observation group were significantly lower than those in the control group(P<0.05);the LVEF levels were significantly increased in two groups (P<0.05),and the LVEF levels in the observation group was significantly higher than those in the control group (P<0.05);the levels of hs-CRP,TNF-α and IL-18 were significantly decreased in two groups (P<0.05),and the levels of hs-CRP,TNF-α and IL-18 in the observation group were significantly lower than those in the control group(P<0.05);the levels of Ang Ⅱ,AVP and ALD were significantly decreased in two groups (P<0.05),and the levels of Ang Ⅱ,AVP and ALD in the observation group were significantly lower than those in the control group (P<0.05).Conclusion Rosuvastatin combined with metoprolol can significantly improve cardiac function and decrease plasma NT-proBNP levels in patients with coronary heart disease and heart failure.The mechanism may be related to its effects in down-regulating inflammatory factors and neuroendocrine levels,and inhibiting myocardial remodeling.
查看全文     
关闭
分享按钮